Amphastar Pharma gains on FDA approval of generic glucagon in low blood sugar

 

• The FDA has approved Amphastar Pharmaceuticals' (NASDAQ:AMPH) first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low blood sugar), occurring mostly in diabetes patients.
• The drug is also indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel and colon.
• Novo Nordisk (NYSE:NVO) manufactures the GlucaGen HypoKit and Eli Lilly (NYSE:LLY) manufactures the Glucagon emergency kit.
• https://seekingalpha.com/news/3647627-amphastar-pharma-gains-10-on-fda-approval-of-generic-glucagon-in-low-blood-sugar